The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -60.55 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -4.01 — no flag raisedOK
- Earnings quality 48/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Emmaus Life Sciences, Inc. reports it. History and quarterly detail are in the app.
- Endari US$9.0M
- Endari International$3.2M
- Product And Service Other$225K
Leadership changes
From Emmaus Life Sciences, Inc.'s own filings, the day they're filed.
- Henry H. Du · Directors · departureeff. 2026-04-16
- Jon Kuwahara · director · departureeff. 2026-04-15
- Ian Zwicker · director · departureeff. 2025-12-31
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-14
- 10-Q · Quarterly report2026-05-15
- 8-K · Company announcement2026-05-15
- 8-K · Company announcement2026-04-17
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Emmaus Life Sciences, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Emmaus Life Sciences, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.